Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $2.7 million, down from $5.4 million in Q3 2024, primarily due to restructuring efforts [15] - Gross profit for Q3 2025 was $1.3 million, or 49% of revenue, compared to $3.1 million, or 58% of revenue in Q3 2024 [15] - Operating expenses were $10.9 million, a decrease of 29% compared to the prior year, with an operating loss of $9.6 million, narrowed by 22% year-over-year [9][10] - Adjusted net operating loss was $6.9 million, a 39% improvement compared to the prior year [10][17] Business Line Data and Key Metrics Changes - The restructuring in Q3 focused on accounts and distributors promoting metabolically healthy weight loss, which is expected to lead to long-term growth [7][8] - Sales and marketing expenses decreased to $3.1 million from $5.2 million in Q3 2024, driven by increased operational efficiency [15][16] - Research and development expenses were reduced to $2.0 million from $3.2 million in Q3 2024, reflecting cost reductions related to the Audacity trial [16] Market Data and Key Metrics Changes - The company is seeing a trend where patients who discontinue GLP-1 treatments represent a significant opportunity for Allurion, as over half of these patients seek alternative therapies [9][18] - The company anticipates that the reduction in GLP-1 prices in the U.S. will drive more uptake and subsequently increase churn rates, leading to more patients looking for alternative therapies [27] Company Strategy and Development Direction - The company is advancing preparations for the U.S. launch of the Allurion Smart Capsule, with a focus on combination therapies with low-dose GLP-1s [6][11] - Allurion is exploring the development of a drug-eluting balloon in collaboration with a strategic partner, which could address adherence challenges in obesity therapy [12][19] - The company is retooling its R&D pipeline and manufacturing capabilities to enhance operational efficiency and expand capacity [11][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the FDA approval process for the Allurion Smart Capsule, highlighting successful inspections and a positive Day 100 meeting outcome [5][6] - The company believes that the Allurion program is uniquely positioned to capitalize on the success of GLP-1s and set the stage for long-term growth in the obesity management market [18][19] Other Important Information - As of September 30, 2025, cash and cash equivalents were $6.1 million, not including a recent private placement financing of $5 million [17] - The company is on a path to being debt-free through a transaction to exchange outstanding debt for convertible preferred equity [10][11] Q&A Session Summary Question: How is the company applying learnings from international strategy to the U.S. market? - Management noted that they are learning from international experiences, particularly regarding the churn rates of GLP-1 patients, and are mapping out U.S. clinics that utilize GLP-1s [21][23] Question: What is the outlook for international revenues over the next 12 to 24 months? - Management expects continued growth in Q4 and into 2026 as clinics embrace GLP-1s and combination therapies [25][26] Question: Can you provide details on the development program for the Smart Capsule as a platform technology? - Management discussed the potential of the Smart Capsule to deliver various drugs and the initiation of a longer-term balloon project that could last beyond four months [29][32]

Financial Data and Key Metrics Changes - Research and development expenses totaled $5.3 million, down from $6.2 million in Q2 2025 and $6 million in Q3 2024, reflecting the completion of the SHIELD II phase 3 trial [12] - General and administrative expenses were $1.8 million, compared to $1.2 million in Q3 2024, while marketing and business development expenses increased to $0.4 million from $0.2 million in the same period last year [12] - The net loss for the quarter was $7.5 million, or $0.37 per share, an improvement from the net loss of $7.8 million, or $1.22 per share in Q3 2024 [12] - For the nine months ended September 30, 2025, net loss was $25.7 million, or $1.72 per share, compared to $20.5 million, or $3.82 per share for the same period in 2024 [13] Business Line Data and Key Metrics Changes - The successful completion of the Israeli Ministry of Health Good Manufacturing Practice inspection marked an important step towards commercial manufacturing readiness for D-PLEX100 [6] - A new US market access study confirmed strong interest from both surgeons and hospital pharmacy directors, with 80% of surgeons indicating they are extremely likely to use D-PLEX100 for their next eligible patients [10] Market Data and Key Metrics Changes - The market access study showed that D-PLEX100 was viewed as more valuable than current SSI prevention measures, with 70% of hospital pharmacy directors reporting a high likelihood to add and stock D-PLEX100 [10] - The study indicated that D-PLEX100 addresses a significant unmet need in the market for surgical site infection prevention [10] Company Strategy and Development Direction - The company is focused on bringing D-PLEX100 to market, with a pre-NDA meeting with the FDA scheduled for early December and an NDA submission expected in early 2026 [5] - Strategic discussions with potential US partners are ongoing, building on the positive momentum from the SHIELD II trial results [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in passing the upcoming FDA inspection, highlighting ongoing improvements in facility and quality control processes [17] - The company anticipates that the pre-NDA meeting will align on the data package and submission format, setting the stage for an early 2026 submission [24] Other Important Information - The company reported a cash balance of $18.8 million as of September 30, 2025, up from $15.6 million at year-end 2024, indicating a strong cash runway into 2026 [14] - Significant progress was made in reducing debt, with current maturities decreasing from $6.5 million to $2.4 million [15] Q&A Session Summary Question: Insights on the Israeli Ministry of Health inspection - Management confirmed the successful inspection and expressed confidence in passing the upcoming FDA inspection, noting ongoing improvements in their facility [17] Question: Specific items for the pre-NDA meeting - The focus will be on reviewing the data package, submission format, and label scope to ensure alignment with the FDA [24] Question: Pricing strategy for D-PLEX100 - Management indicated strong interest in premium pricing based on market research and stakeholder feedback, suggesting that there is room to stretch pricing higher [26] Question: Growth of the PolyPid pipeline post-partnership - Management outlined plans for expanding the pipeline in oncology, obesity, and diabetes, while also emphasizing the importance of a US partner for the abdominal indication [33] Question: Market research sample size and decision-making involvement - The market research included 20 participants, all of whom were involved in the decision-making process regarding formulary inclusion [42] Question: Challenges in commercializing D-PLEX100 in the U.S. - Management acknowledged the need for future facility expansion to meet peak sales demands and is considering local manufacturing trends in their planning [46]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported revenue of approximately $1.2 million from 2,841 EsoGuard tests, maintaining volume and revenue levels consistent with the previous quarter [5][22] - The quarterly burn rate was $10.3 million, slightly better than the average burn rate of the previous four quarters [22][28] - The company ended the quarter with $47.3 million in cash, bolstered by a public offering that netted approximately $27 million [9][22] Business Line Data and Key Metrics Changes - EsoGuard test volume remained within the target range of 2,500-3,000 tests per quarter, essential for ongoing engagements with commercial payers [5][8] - Revenue recognition for the majority of claims is based on the probability of collection, with 76% of claims submitted in Q3 adjudicated [26][30] Market Data and Key Metrics Changes - The company is focusing on expanding its market access, particularly targeting Medicare patients, which represent about 50% of the 30 million target population [7][8] - The company has strengthened its market access leadership team to enhance payer engagement and secure broader commercial insurance coverage [6][11] Company Strategy and Development Direction - The company is in the final stages of securing positive Medicare coverage policy outcomes, following a successful Contractor Advisory Committee meeting [4][9] - The strategy includes transitioning to target Medicare patients while maintaining volume with commercial payers [5][8] - The company is also hosting events to strengthen relationships with fire departments, focusing on esophageal cancer prevention [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming Medicare coverage, anticipating a draft local coverage determination soon [12][14] - The company is actively engaging with commercial payers and has seen positive movement in discussions, indicating a shift in strategy to pursue coverage even before Medicare approval [45][48] Other Important Information - The company has a strong pipeline of contracted testing events and is expanding its efforts to drive Medicare testing [20][19] - The company reported a non-GAAP net loss of $10.3 million for Q3, consistent with previous quarters [28][30] Q&A Session Summary Question: Can you provide insights on the recent CCLA meeting and its implications? - Management highlighted that the meeting was positive, with significant time spent discussing the company's CAC meeting, reinforcing confidence in the Medicare coverage process [34][35] Question: What is the expected timeline for the draft LCD? - Management indicated that they believe the timeline for the draft LCD publication is reasonable, with expectations for it to be issued by year-end 2025 [43][44] Question: How is the company engaging with commercial payers? - Management noted that there has been increased activity and positive movement in discussions with commercial payers, with expectations for positive coverage policies to emerge soon [45][48] Question: What is the conversion rate for referrals to EsoGuard tests? - Management stated that the conversion rate for patients referred for EsoGuard tests is over 90%, indicating strong follow-through on testing [78]

Financial Data and Key Metrics Changes - In Q3 2025, net product revenue was $21.1 million, slightly up from $20.9 million in Q2 2025. Deferred revenue increased to $7.6 million from $2.1 million in Q2 2025, indicating a healthy backlog of products ready for infusion [28][29]. - Cost of sales for Q3 2025 totaled $28.6 million, while research and development expenses decreased to $27.9 million from $40.3 million in Q3 2024. Selling, general, and administrative expenses rose to $36.3 million from $27.3 million in the same period [29][30]. - The net loss for Q3 2025 was $79.1 million, reduced from a loss of $82.1 million in Q3 2024. Cash, cash equivalents, and marketable securities totaled $367.4 million, down from $588 million at the end of December 2024 [31][32]. Business Line Data and Key Metrics Changes - The launch of AUCATZYL in the U.S. achieved $21.1 million in net sales for Q3 2025, with total sales of $51 million for the first nine months of the year. The company has established 60 treatment centers, achieving over 90% patient access for U.S. covered lives [6][7][28]. - The manufacturing success rate is above 90%, and the company is focusing on optimizing operations and driving efficiencies [5][7]. Market Data and Key Metrics Changes - The CAR-T market share for the treatment of relapsed refractory B-cell ALL is approximately 20% within the 60 treatment centers, indicating significant growth potential as the majority of patients are still not receiving CAR-T therapy [8][58]. - The company is expanding its pipeline with ongoing studies in pediatric ALL, lupus nephritis, and progressive multiple sclerosis, indicating a strategic focus on diversifying its product offerings [6][18]. Company Strategy and Development Direction - The company aims to drive market share in adult ALL, improve margins, and expand beyond ALL into other indications. There is a focus on building relationships with treatment centers to enhance product uptake [4][6][33]. - The management is optimistic about the growth potential in the CAR-T market and is leveraging data collected from the initial launch phase to optimize processes and drive efficiencies [5][8]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing commercial launch of AUCATZYL, highlighting positive feedback from physicians and the establishment of a reliable product delivery system [4][5]. - The company anticipates key data points from ongoing trials to be presented at the ASH conference, which could further validate its product offerings and market position [33][70]. Other Important Information - The company has made significant leadership changes, appointing new key members to enhance its operational capabilities and drive future growth [10][11]. - The management emphasized the importance of innovation in manufacturing and market access to serve a larger patient population [16]. Q&A Session Summary Question: Can you talk about the patient flow and anticipated patient flow going forward? - Management noted a good proportion of patients were not initially considered for CAR-T therapy, indicating an expansion of market penetration [35][36]. Question: How does the competitive positioning for Obe-cel in pediatric patients compare to adults? - The focus is on high-risk pediatric patients who are not eligible for CAR-T therapy, with a strong safety and efficacy profile expected to drive interest [39][40]. Question: What drove the flat performance in Q3 compared to Q2? - The flat performance was influenced by a CMS reimbursement policy change that affected patient enrollment, but deferred revenue indicates a healthy pipeline for Q4 [46][50]. Question: Can you provide insights on CAR-T share growth and the competitive landscape in autoimmune diseases? - The company sees significant growth potential in CAR-T therapy as many patients are still untreated, and it believes it is well-positioned in the competitive landscape of autoimmune diseases [57][63]. Question: What data is expected at the ASH conference? - The company will present data from the pediatric ALL study and the Carlyle study, focusing on safety, efficacy, and long-term outcomes [69][70].

Financial Data and Key Metrics Changes - The cash balance and restricted cash as of September 30, 2025, were $8.1 million, down from $18 million as of December 31, 2024, primarily due to net cash used in operating activities [11] - Research and development expenses net were $6.1 million for Q3 2025, compared to $7.3 million for Q3 2024, driven by reduced salary expenses and lower rent expenses [12] - General and administrative expenses were $2.4 million for Q3 2025, down from $3.2 million for Q3 2024, mainly due to reduced salary and share-based compensation expenses [13] - The net loss for Q3 2025 was $9.2 million, compared to a net income of $9.6 million for Q3 2024, primarily due to changes in the fair value of warrants [13] Business Line Data and Key Metrics Changes - The BX004 program for cystic fibrosis patients made significant progress despite regulatory challenges, with first patient dosing in the phase IIB trial [5] - The BX011 program targeting Staphylococcus aureus infections in diabetic foot infections received positive FDA feedback, supporting its development as an off-the-shelf formulation [8][9] Market Data and Key Metrics Changes - Approximately 160,000 lower limb amputations occur annually in diabetic patients in the U.S., with 85% stemming from diabetic foot infections or osteomyelitis, highlighting a significant unmet medical need [9] Company Strategy and Development Direction - The company is focused on advancing both BX004 and BX011 through key upcoming milestones, with a clear phase III development pathway for BX004 and a strong regulatory opportunity for BX011 [14] - The strategy includes leveraging existing clinical data and addressing critical unmet medical needs in the diabetic foot infection market [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about resuming enrollment in the BX004 trial following FDA feedback, viewing the clinical hold as a technical challenge rather than a fundamental concern [6][7] - The company sees strong momentum in the phage therapy field and increasing validation of phage-based approaches, which strengthens confidence in upcoming trial readouts [10] Other Important Information - The FDA provided constructive guidance for BX011, outlining a clear potential pathway toward a biologics license application without the need for additional non-clinical studies [9] Q&A Session Summary Question: Clarification on the defense potential for BX011 - Management indicated that the U.S. Defense Health Agency supports the approval of BX011 through a commercial indication first, with potential expansion later [17][19] Question: Outstanding questions regarding DFI design or inclusion criteria - Management confirmed that there are some fine-tuning aspects but generally good clarity on the clinical study design and endpoints [21][22] Question: Speculation on the FDA's initial clinical hold for BX004 - Management speculated that the hold was due to new requirements for the nebulizer device, viewing it as a technical issue rather than a concern about the drug itself [34] Question: General ideas on the size and duration of the potential phase III study for BX004 - Management indicated that while specifics are still being defined, there is a clear understanding of the phase III study's direction, pending positive data from the phase IIB trial [36]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $110.5 million, representing an 8% year-over-year growth [15] - Contribution ex-TAC was $51 million, up 7% year-over-year, maintaining a healthy 46% margin [15][20] - Adjusted EBITDA increased 63% year-over-year to $12.1 million, reflecting improved operational leverage [14][20] - Non-GAAP net income was $12.5 million, resulting in a non-GAAP diluted earnings per share of $0.28, a 22% year-over-year increase [21] Business Line Data and Key Metrics Changes - CTV revenue grew 75% year-over-year, driven by demand for advanced formats [17] - Retail media revenue increased by 40% year-over-year, reflecting strong momentum in this vertical [18] - Digital out-of-home revenue rose 26% year-over-year, now accounting for 22% of total revenue [18][19] - Web revenue declined by 11% year-over-year due to lower advertiser appetite for standard display and video formats [19] Market Data and Key Metrics Changes - The retail media market in the US is projected to be a $60 billion opportunity, growing at double-digit annual rates [8] - CTV and digital out-of-home channels combined represented 37% of total revenue, up from 28% in the same quarter last year [18] Company Strategy and Development Direction - The company is focused on becoming the platform of choice for modern CMOs, unifying media, data, and outcomes through the Perion One strategy [5][6] - New products like Outmax and Soda are designed to enhance performance-driven advertising and optimize monetization for publishers [4][10] - The company is expanding its share repurchase program to $200 million, reflecting confidence in long-term value [3][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth and profitability, supported by operational efficiency and scalable technology [15][24] - The company aims to capture more market share in 2026 and beyond, with expectations for continued strong performance from core growth engines [27][30] Other Important Information - The company has a strong cash position of $315 million, providing financial flexibility for growth and capital allocation [22] - The share buyback program has repurchased a cumulative total of 10.4 million shares for $94.2 million, underscoring confidence in long-term value [22][23] Q&A Session Summary Question: What are the drivers behind the CTV strength in Q3? - Management noted that performance CTV and the new algorithm, Outmax, are performing well, contributing to significant growth [26] Question: Why is the Q4 guidance range wide? - Management indicated that the quarter is trending in line with expectations and expressed confidence in meeting guidance during the holiday season [27] Question: How does the company view the web business decline? - Management clarified that the web business decline was primarily due to strategic decisions made earlier in the year, and they expect a potential return to growth in the future [38] Question: How is the company using AI internally? - Management stated that AI is increasingly integrated into R&D and operations, aiming to reduce manual work and enhance efficiency [40] Question: What is the potential of Soda and the Digital Out-of-Home Player? - Management explained that these products are designed to be integrated into the tech stack of inventory owners, increasing predictability and visibility into revenue streams [42]

Financial Data and Key Metrics Changes - Third quarter revenue reached $473.9 million, reflecting substantial year-over-year growth, primarily due to two months of NV5's contribution following the acquisition [17] - On a combined basis, year-to-date revenue growth was approximately 4.7% [17] - Adjusted gross profit was approximately $171 million, with an adjusted gross margin of 36.1%, up from the prior year [19] - Adjusted EBITDA for the third quarter was $77.3 million, representing an adjusted EBITDA margin of 16.3% [20] Business Line Data and Key Metrics Changes - The Inspection and Mitigation segment generated approximately $293 million in revenue, down about 3% year-over-year [18] - The Consulting Engineering segment contributed approximately $122 million during the two-month period, with potential revenue of approximately $189 million if NV5's results were included for the full quarter, reflecting an 11% increase [18] - The Geospatial segment contributed about $62 million during the same period, with potential revenue of about $90 million if MB5 results were included for the full quarter, approximately 4% higher than last year [19] Market Data and Key Metrics Changes - The company reported double-digit growth in the consulting engineering segment, driven by data center work for hyperscaler clients, which more than doubled over the trailing twelve months [9] - Infrastructure investments supporting grid modernization and energy transition are creating new opportunities across all segments [10] Company Strategy and Development Direction - The company aims to capture meaningful synergies as integration actions move into 2026, focusing on disciplined execution and long-term growth [6][14] - The strategic vision includes expanding markets served and services provided within the TIC and engineering space [6] - The company is positioned to benefit from secular tailwinds such as infrastructure renewal and energy transition [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in demand across core markets and reaffirmed full-year 2025 guidance, expecting revenue between $1.53 billion and $1.565 billion [23] - The company anticipates revenue growth of 35% relative to the 2025 combined company baseline for the following year [24] - Management highlighted the importance of maintaining operational excellence and customer service during the integration process [30] Other Important Information - The company increased its cost synergy target from $20 million to $25 million, expected to be fully realized by mid-2027 [25] - Total liquidity as of September 30, 2025, was $282.9 million, including cash and cash equivalents of $164.4 million [22] Q&A Session Summary Question: What is the reasonable range for annual free cash flow after integration? - Management indicated that the business continues to be a high free cash flow business with low CapEx and high margins, but did not provide specific guidance on free cash flow [36] Question: Is the $400 million revenue target for data centers still in place? - Management confirmed that the data center business is growing significantly, with revenue up over 100% year-to-date, and they are excited about future growth opportunities [38] Question: What is the impact of the government shutdown on geospatial services? - Management noted limited impact from the government shutdown, with optimism for a quick reopening and resumption of work orders [46][47] Question: How is the turnaround activity trending in Q4? - Management stated that turnaround activity has not materially changed and is primarily affected by the timing of LNG projects [51] Question: Can you provide more details on the increased synergy target? - Management clarified that the increased synergy target of $25 million is purely cost synergies, primarily from back office support and organizational efficiencies [56] Question: What are the growth opportunities in the business? - Management highlighted the potential for cross-selling opportunities and filling white space in the total value chain as significant growth areas [88]

Financial Data and Key Metrics Changes - Third quarter revenue reached $473.9 million, reflecting substantial year-over-year growth, primarily due to two months of NV5's contribution following the acquisition [13][15] - Year-to-date growth for the combined business was approximately 4.7%, with a quarter growth of about 2.4% if the acquisition had occurred on January 1, 2024 [13][19] - Adjusted EBITDA for the third quarter was $77.3 million, representing an adjusted EBITDA margin of 16.3%, compared to $51.3 million with a margin of 16.9% in the prior year [17][19] Business Line Data and Key Metrics Changes - The inspection and mitigation segment generated approximately $293 million in revenue, down about 3% year-over-year, while the consulting engineering segment contributed approximately $122 million during the two-month period, with a potential full quarter revenue of about $189 million, reflecting an 11% increase [15][16] - The geospatial segment contributed about $62 million during the same two-month period, with a potential full quarter revenue of approximately $90 million, up about 4% year-over-year [16] Market Data and Key Metrics Changes - The company reported double-digit growth in the consulting engineering segment, driven by data center work for hyperscaler clients, which more than doubled over the trailing 12 months [8][9] - Infrastructure investments supporting grid modernization and energy transition are creating new opportunities across all three segments, indicating multi-year growth drivers [9][12] Company Strategy and Development Direction - The company aims to expand the markets served and services provided within the TIC and engineering space, focusing on a unified platform dedicated to reliability, innovation, and service excellence [5][6] - The integration of Acuren and NV5 is expected to create synergies and enhance capabilities, allowing the company to serve clients across the full lifecycle of critical assets and infrastructure [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand across core markets and reaffirmed full-year 2025 guidance, expecting revenue in the range of $1.530 billion to $1.565 billion [19][20] - The company anticipates revenue growth of 3% to 5% relative to the 2025 combined company baseline for the following year [19] Other Important Information - The company has increased its cost synergy target from $20 million to $25 million, expected to be fully realized by mid-2027 [21][22] - Total liquidity as of September 30, 2025, was $282.9 million, including cash and cash equivalents of $164.4 million [18] Q&A Session Summary Question: What is the reasonable range for annual free cash flow after integration? - Management highlighted that the business is a high-free cash flow business with low CapEx and high margins, but specific guidance on free cash flow has not been provided [28][29] Question: Is the $400 million revenue target for data centers still in place? - Management confirmed that the data center business has seen over 100% growth year-to-date and remains a significant focus area [30][31] Question: What is the status of exiting lower-margin customer contracts? - Management indicated that the softness in the third quarter was primarily timing-related and that they continue to evaluate relationships for margin improvement [32] Question: How has the government shutdown impacted the geospatial segment? - Management noted limited impact from the government shutdown, with optimism for a quick reopening and resumption of work orders [35][36] Question: What is the outlook for the chemical market and its impact on guidance? - Management expects stabilization in the chemical space and is optimistic about delivering results in Q4 and next year [56][57] Question: What are the drivers for the increased synergy target? - Management clarified that the increased target is purely cost synergies, focusing on back-office support and organizational efficiency [43][44] Question: Where does the company see the most growth opportunities? - Management highlighted the potential in filling white space between segments and expanding in Canada as key growth areas [68][70]

Financial Data and Key Metrics Changes - System-wide sales for Q3 2025 were $238.2 million, a decrease of 0.8% year-over-year, primarily due to closed centers [20][22] - Same-store sales grew by 20 basis points year-over-year [20] - Adjusted EBITDA increased by 9.6% to $20.2 million from $18.4 million in the prior year, with an adjusted EBITDA margin increase of 400 basis points to 37.2% [23] - Total revenue decreased by approximately $1.2 million, or 2.2%, primarily driven by lower contributions from wholesale product and retail revenue [22] - SG&A expenses decreased by $4.5 million to $13 million, reflecting timing of payroll and benefits, professional fees, and marketing spend [23] Business Line Data and Key Metrics Changes - The company opened three growth centers during the quarter and closed nine, resulting in six net closures, which was better than the expected closure range of 15-16 [22] - Wax Pass sales saw a slight year-over-year uptick, indicating stability in core guest engagement [39] Market Data and Key Metrics Changes - Com trends were strong through July and mid-August before softening in the latter half of August and September [21] - Regional performance showed improvement in California, while areas like New York, Philadelphia, and D.C. experienced more weakness [39] Company Strategy and Development Direction - The company is focused on three strategic priorities: driving sales through traffic growth, improving four-wall profitability for franchisees through operational excellence, and pursuing disciplined, profitable expansion [7][15] - A new brand agency has been brought on to refine brand identity and connect with high-value audiences, with initiatives expected to scale meaningfully in 2026 [12][56] - The company is narrowing its closure range to between 35 and 40 for the year, reflecting improved franchisee partnerships and strategic initiatives [25][41] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed full-year financial guidance, expecting system-wide sales of $940-$950 million and same-store sales to be flat to up 1% for the full year [26][27] - The company anticipates continued pressure on new guest acquisition but expects improvement in 2026 [26][28] - Management expressed confidence in the strategic groundwork established, which is beginning to take hold and position the company for sustainable long-term growth [28][29] Other Important Information - The company ended Q3 with 1,053 centers, down 1% year-over-year, and had $73.6 million in cash with a net leverage ratio of 3.9 times [22][24] - The company continues to expect adjusted net income between $31 million and $33 million, reflecting an approximately 23% effective tax rate before discrete items [27] Q&A Session Summary Question: Can you quantify the lift from revamped marketing efforts? - Management noted that they have improved contactability from 38% to 60% of guests, which has enhanced engagement and driven frequency improvements [32][33] Question: What trends are observed in Wax Pass sales and regional performance? - Wax Pass sales have seen a slight uptick year-over-year, with stability in the core guest base, while California has shown improvement compared to New York, Philadelphia, and D.C. [39] Question: What are the expectations for center openings and closures moving forward? - Management indicated that they are pleased to narrow the closure range and expect closures in early 2026 but anticipate returning to net positive growth by the end of 2026 [41][42] Question: What factors are contributing to the confidence in alleviating pressures on closures? - The closures are primarily low-volume units due to various factors, and management has a good grip on the overall health of the portfolio, which gives them confidence moving forward [46][48] Question: What is the approach to balancing guest count and ticket growth? - Management emphasized a balanced approach to driving traffic and ticket growth, focusing on both increasing guest count and smart pricing strategies [59][60]

Financial Data and Key Metrics Changes - USDC in circulation grew 108% year-over-year to $73.7 billion, indicating strong market share expansion [8][23] - Total revenue and reserve income increased 66% year-on-year to $740 million, with adjusted EBITDA growing 78% year-on-year to $166 million, reflecting a 57% adjusted EBITDA margin [9][25] - Reserve return rate was 4.15%, down 96 basis points year-on-year due to a decline in SOFR [23] Business Line Data and Key Metrics Changes - Circle Payments Network (CPN) saw significant growth in transaction volumes, with over 100x growth in monthly total payment volume since its launch [21][20] - CCTP (Cross-Chain Transfer Protocol) volume grew approximately 640% year-over-year to $31.3 billion in Q3 [12][13] - Subscription and services revenue reached $23.6 million, primarily from blockchain network partnerships, with strong growth in underlying recurring revenues [24][83] Market Data and Key Metrics Changes - The stablecoin market continued to grow, with Circle's share increasing to 29% in Q3, up from 28% in the previous quarter [10][42] - Stablecoin transaction volumes grew approximately 130% year-over-year, with USDC's share expanding to 40% [11] - On-chain transactions using USDC grew 580% year-over-year to $9.6 trillion in Q3 [9] Company Strategy and Development Direction - Circle aims to build a full-stack Internet financial platform, focusing on blockchain networks, digital assets, and application utilities [5][8] - The company is exploring the launch of a native token on the Arc network to drive utility, incentives, and governance [10][18] - Circle continues to expand its stablecoin network across more chains, with five new chain launches and a total of 28 supported chains [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth of USDC circulation and the overall stablecoin market, driven by regulatory clarity and technological advancements [26][43] - The company is focused on building partnerships with quality participants to enhance the value of its network [32][60] - Management does not provide detailed quarterly guidance but has increased full-year guidance for other revenue to $90-$100 million [26][27] Other Important Information - The Arc public testnet launched with over 100 major participants from various sectors, indicating strong interest and collaboration [17] - The company has seen strong early momentum for Circle Payments Network, with a growing pipeline of financial institutions seeking to join [19][20] - Circle has closed three M&A deals this year, focusing on accelerating its core offerings rather than diversifying [68][69] Q&A Session Summary Question: Insights on Circle Payments Network (CPN) pipeline and monetization - Management highlighted the focus on quality participants and operational capabilities for CPN, emphasizing the importance of meaningful flows [30][32] - Monetization will focus on growing the network rather than extracting immediate value, with potential for small fees in the future [34][35] Question: Reaction to Fed's involvement in payments and crypto - Management expressed alignment with the Fed's view, stating that Circle's infrastructure is fundamental to the emerging on-chain financial system [40][41] Question: Market share gains and regulatory impact - Management noted that growth in market share is driven by regulatory clarity and advancements in technology, leading to increased adoption by major financial institutions [42][43] Question: Exploration of a native token for Arc - Management discussed the potential benefits of a native token for Arc, focusing on stakeholder incentives and governance [48][50] Question: Demand-side insights and M&A interest - Management indicated that strong direct liquidity and efficient capital movement are critical for firms looking to build on stablecoin payments [65][68] Question: Subscription revenue growth and transaction revenue decline - Management explained that subscription revenue growth is driven by blockchain partnerships, while the decline in transaction revenue was due to a spike in the previous quarter related to redemptions [84][85]